Dr. Ebbinghaus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
333 Cottman Avenue
Fox Chase Cancer Cenetr
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-728-3639- Is this information wrong?
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996- University of Alabama Medical CenterResidency, Internal Medicine, 1989 - 1993
University of Missouri Kansas City School of MedicineClass of 1989
Certifications & Licensure
PA State Medical License 2007 - 2024
AZ State Medical License 2000 - 2009
AL State Medical License Active through 2007
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Study Evaluating the Safety and Tolerability of L-377202 Start of enrollment: 1999 Mar 01
Publications & Presentations
PubMed
- Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc...> ;Journal for Immunotherapy of Cancer. 2023 May 1
- 8 citationsModernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group.R. Donald Harvey, Kathryn Finch Mileham, Vishal Bhatnagar, Jamie Renee Brewer, Atiqur Rahman, Cassadie Moravek, Andrew S. Kennedy, Elizabeth Ness, E. Claire Dees, S. P...> ;Clinical Cancer Research. 2021 Feb 9
- 153 citationsPembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim anal...Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, Lynley V. Marshall, Catherine Vezina, Alberto S. Pappo, Theodore W. Laetsch, Antonio Sergio Petrilli, Martin Ebing...> ;The Lancet. Oncology. 2020 Jan 1
- Join now to see all
Authored Content
- Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients with Advanced Melanoma Treated with Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical TrialAugust 2018
Press Mentions
USFDA Accepts Application for Merck KEYTRUDA plus Chemotherapy as First Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaApril 13th, 2023- Merck Keytruda Gets Full USFDA Approval for Advanced MSI-H or dMMR Solid TumorsApril 1st, 2023
- Experts Discuss Importance of Cancer Screenings and Early DetectionAugust 11th, 2022
- Join now to see all
Grant Support
- Site Specific Alkylation Of The Her2/Neu PromoterNational Cancer Institute2002–2004
- Specific Inhibition Of Her2/Neu Transcription ElongationNational Cancer Institute2000–2002
- Specific Inhibition Of Her2/Neu Transcription ElongationNational Cancer Institute1998–2000
- Triplex Based Gene Therapy Of Breast And Ovarian CancerNational Cancer Institute1996–1998
Hospital Affiliations
Fox Chase Cancer CenterPhiladelphia, Pennsylvania
Temple University HospitalPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
